drugset / Trial / NCT00036660

SarCNU in Treating Patients With Recurrent Malignant Glioma

NCT00036660 ↗

Phase 2 Completed 10 enrolled NCIC Clinical Trials Group
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of sarCNU in treating patients who have recurrent malignant glioma.

Timeline

Start
2002-01-10
Primary completion
2003-04-15
Completion
2008-09-22

Drugs

EvaluationDrugModalityDoseRoute
Subject SarCNU Small molecule 860 mg/m2 Oral